Lumos Pharma, Inc. announced that Chief Medical Officer (CMO) Dr. David B. Karpf is departing the company to pursue other opportunities, effective June 29th. Dr. Pisit âDukeâ Pitukcheewanont, Lumos Pharmaâs Senior Vice President, Global Clinical Development and Medical Affairs, along with other members of clinical team, will oversee all clinical activities and related functions until a CMO search is complete.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.35 USD | +3.52% | +1.73% | -26.10% |
04/06 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
15/05 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.10% | 1.91Cr | |
+55.70% | 5.93TCr | |
+43.17% | 4.02TCr | |
-5.39% | 3.99TCr | |
-5.56% | 2.86TCr | |
+16.46% | 2.73TCr | |
-20.56% | 1.92TCr | |
+33.03% | 1.26TCr | |
+25.85% | 1.23TCr | |
+2.72% | 1.25TCr |
- Stock Market
- Equities
- LUMO Stock
- News Lumos Pharma, Inc.
- Lumos Pharma, Inc. Announces Departure of David B. Karpf, Chief Medical Officer, Effective June 29, 2023